Abstract
Inborn errors of bile acid synthesis are rare genetic disorders that can present as neonatal cholestasis, neurologic disease or fat-soluble-vitamin deficiencies. There are nine known defects of bile acid synthesis, including oxysterol 7α-hydroxylase deficiency, Δ4-3-oxosteroid-5β-reductase deficiency, 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency, cerebrotendinous xanthomatosis (also known as sterol 27-hydroxylase deficiency), α-methylacyl-CoA racemase deficiency, and Zellweger syndrome (also known as cerebrohepatorenal syndrome). These diseases are characterized by a failure to produce normal bile acids and an accumulation of unusual bile acids and bile acid intermediaries. Individuals with inborn errors of bile acid synthesis generally present with the hallmark features of normal or low serum bile acid concentrations, normal γ-glutamyl transpeptidase concentrations and the absence of pruritus. Failure to diagnose any of these conditions can result in liver failure or progressive chronic liver disease. If recognized early, many patients can have a remarkable clinical response to oral bile acid therapy.
Key Points
-
Defects in bile acid synthesis most commonly present as neonatal cholestasis or neonatal hepatitis, but can present as chronic liver disease in older children
-
Unlike most cholestatic diseases, patients with bile acid synthesis defects generally have the hallmark features of low or normal serum bile acid levels, normal or minimally increased γ-glutamyl transpeptidase levels and lack of pruritus
-
Deficiency of Δ4-3-oxosteroid-5β-reductase can present as either neonatal cholestasis or as liver failure that resembles neonatal hemochromatosis; it has a 50% mortality in infants when diagnosis is delayed
-
Deficiency of 3β-hydroxy-Δ5-C27-steroid dehydrogenase is the most common defect of bile acid synthesis, presenting both as neonatal cholestasis and as chronic liver disease in older patients
-
Cerebrotendinous xanthomatosis is a lipid storage disorder that presents with symptoms of progressive neurologic dysfunction in the second or third decade of life and occasionally as neonatal cholestasis; it can be treated with oral bile acids
-
Early recognition and diagnosis of bile acid synthesis defects is important as these disorders are often readily treatable with oral bile acid therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bove KE et al. (2004) Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol 7: 315–334
Westin S et al. (2005) FXR, a therapeutic target for bile acid and lipid disorders. Mini Rev Med Chem 5: 719–727
Edwards PA et al. (2002) BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 43: 2–12
Otte K et al. (2003) Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 23: 864–872
Makishima M et al. (1999) Identification of a nuclear receptor for bile acids. Science 284: 1362–1365
Parks DJ et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365–1368
Wang H et al. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543–553
Goodwin B et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517–526
Kuipers F et al. (2004) The farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev Endocr Metab Disord 5: 319–326
Vlahcevic ZR et al. (1999) Regulation of bile acid biosynthesis. Gastroenterol Clin North Am 28: 1–25
Russell DW et al. (1992) Bile acid biosynthesis. Biochemistry 31: 4737–4749
Ichimiya H et al. (1991) Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment. J Lipid Res 32: 829–841
Ichimiya H et al. (1990) Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. Arch Dis Child 65: 1121–1124
Setchell KD et al. (1998) Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 102: 1690–1703
Schwarz M et al. (1996) Disruption of cholesterol 7alpha-hydroxylase gene in mice: II. bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J Biol Chem 271: 18024–18031
Schwarz M et al. (1997) Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J Biol Chem 272: 23995–24001
Axelson M and Sjovall J (1990) Potential bile acid precursors in plasma—possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. J Steroid Biochem 36: 631–640
Shoda J et al. (1993) Formation of 7 alpha- and 7-beta-hydroxylated bile acid precursors from 27-hydroxycholesterol in human liver microsomes and mitochondria. Hepatology 17: 395–403
Ishibashi S et al. (1996) Disruption of cholesterol 7alpha-hydroxylase gene in mice: I. postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem 271: 18017–18023
Gonzales E et al. (2004) SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. J Hepatol 40: 716–718
Lemonde HA et al. (2003) Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut 52: 1494–1499
Setchell KD et al. (1988) Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis: a new inborn error in bile acid synthesis. J Clin Invest 82: 2148–2157
Heubi JE et al. (2007) Inborn errors of bile acid metabolism. Semin Liver Dis 27: 282–294
Siafakas CG et al. (1997) Abnormal bile acid metabolism and neonatal hemochromatosis: a subset with poor prognosis. J Pediatr Gastroenterol Nutr 25: 321–326
Shneider BL et al. (1994) Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 124: 234–238
Clayton PT et al. (1996) Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623–628
Levy P et al. (1991) Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats. Gastroenterology 101: 1673–1679
Clayton PT et al. (1988) 3-Oxo-delta 4 bile acids in liver disease. Lancet 1: 1283–1284
Sumazaki R et al. (1997) Gene analysis in delta 4-3-oxosteroid 5 beta-reductase deficiency. Lancet 349: 329
Bove KE et al. (2000) Bile acid synthetic defects and liver disease. Pediatr Dev Pathol 3: 1–16
Daugherty CC et al. (1993) Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency). Hepatology 18: 1096–1101
Bazzoli F et al. (1982) Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey. Dig Dis Sci 27: 417–424
Sarva RP et al. (1980) Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey. Gastroenterology 79: 629–636
Wikvall K (1981) Purification and properties of a 3 beta-hydroxy-delta 5-C27-steroid oxidoreductase from rabbit liver microsomes. J Biol Chem 256: 3376–3380
Clayton PT et al. (1987) Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest 79: 1031–1038
Stieger B et al. (1997) Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. Eur J Biochem 244: 39–44
Buchmann MS et al. (1990) Lack of 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase/isomerase in fibroblasts from a child with urinary excretion of 3 beta-hydroxy-delta 5-bile acids: a new inborn error of metabolism. J Clin Invest 86: 2034–2037
Schwarz M et al. (2000) The bile acid synthetic gene 3beta-hydroxy-delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J Clin Invest 106: 1175–1184
Cheng JB et al. (2003) Molecular genetics of 3beta-hydroxy-delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab 88: 1833–1841
Jacquemin E et al. (1994) A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr 125: 379–384
Horslen SP et al. (1992) 3Beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology. J Inherit Metab Dis 15: 38–46
Witzleben CL et al. (1992) A new category of causes of intrahepatic cholestasis. Pediatr Pathol 12: 269–274
Yamato Y et al. (2001) 3Beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency: diagnosis and treatment. J Paediatr Child Health 37: 516519
Moghadasian MH et al. (2002) Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 59: 527–529
Gallus GN et al. (2006) Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci 27: 143–149
Verrips A et al. (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123: 908–919
Setchell KD and Street JM (1987) Inborn errors of bile acid synthesis. Semin Liver Dis 7: 85–99
Clayton PT et al. (1995) Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis. Pediatr Res 37: 424–431
Cruysberg JR et al. (1991) Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthal 112: 606–607
Wevers RA et al. (1992) Paediatric cerebrotendinous xanthomatosis. J Inherit Metab Dis 15: 374–376
Setchell KDR et al. (2007) Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease. In Liver Disease in Children 736–766 (Eds Suchy FJ. et al.) New York: Cambridge University Press
Moghadasian MH (2004) Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 27: 42–50
Kuriyama M et al. (1991) Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci 102: 225–232
van Heijst AF et al. (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157: 313–316
Bindl L et al. (2001) Cerebrotendinous xanthomatosis presenting as “chologenic diarrhoea”. Acta Paediatr 90: 828–829
von Bahr S et al. (2005) Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr 40: 481–486
Clayton PT et al. (2002) Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25: 501–513
Egestad B et al. (1985) Fast atom bombardment mass spectrometry in the diagnosis of cerebrotendinous xanthomatosis. Scand J Clin Lab Invest 45: 443–446
Samenuk P and Koffman BM (2001) Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology 56: 695–696
Berginer VM et al. (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311: 1649–1652
Batta AK et al. (2004) Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism 53: 556–562
Koopman BJ et al. (1985) Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosi. Clin Chim Acta 152: 115–122
Verrips A et al. (1999) Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48: 233–238
Burnett JR et al. (2001) Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta 306: 63–69
Kuriyama M et al. (1994) Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 125: 22–28
Nakamura T et al. (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40: 741–746
Ferdinandusse S et al. (2002) Reinvestigation of peroxisomal 3-ketoacyl-CoA thiolase deficiency: identification of the true defect at the level of d-bifunctional protein. Am J Hum Genet 70: 1589–1593
Cuebas DA et al. (2002) The role of alpha-methylacyl-CoA racemase in bile acid synthesis. Biochem J 363: 801–807
Ferdinandusse S et al. (2000) Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41: 1890–1896
Ferdinandusse S et al. (2001) Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency. J Lipid Res 42: 137–141
Ferdinandusse S et al. (2000) Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Gen 24: 188–891
Setchell KD et al. (2003) Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 124: 217–232
Van Veldhoven PP et al. (2001) Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency. Eur J Clin Invest 31: 714–722
Wanders RJ et al. (1995) Measurement of peroxisomal fatty acid beta-oxidation in cultured human skin fibroblasts. J Inherit Metab Dis 18 (Suppl 1): S113–S124
Keane MH et al. (2007) Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. Hepatology 45: 982–997
Steinberg SJ et al. (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta 1763: 1733–1748
Watkins PA et al. (2007) Peroxisomal Diseases. In: Liver Disease in Children, 840–857 (Eds Suchy FJ. et al.) New York: Cambridge University Press
Steinberg SJ et al. (1999) Peroxisomal disorders: clinical and biochemical studies in 15 children and prenatal diagnosis in 7 families. Am J Med Genet 85: 502–510
Theil AC et al. (1992) Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients. Eur J Pediatr 151: 117–120
Wilson GN et al. (1986) Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am J Med Genet 24: 69–82
Monnens L et al. (1980) Disturbances in bile acid metabolism of infants with the Zellweger (cerebro-hepato-renal) syndrome. Eur J Pediatr 133: 31–35
Mooi WJ et al. (1983) Ultrastructure of the liver in the cerebrohepatorenal syndrome of Zellweger. Ultrastruct Pathol 5: 135–144
Martinez M (2001) Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 16: 309–316
Martinez M et al. (2000) Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am J Clin Nutr 71 (Suppl 1): S376–S385
Martinez M and Vazquez E (1998) MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 51: 26–32
Setchell KD et al. (1992) Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology 15: 198–207
Maeda K et al. (2002) Oral bile acid treatment in two Japanese patients with Zellweger syndrome. J Pediatr Gastroenterol Nutr 35: 227–230
van Grunsven EG et al. (1998) Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc Natl Acad Sci USA 95: 2128–2133
Wanders RJA et al. (2001) Single peroxisomal enzyme deficiencies. In The Molecular And Metabolic Bases Of Inherited Disease, 3219–3256 (Eds Scriver CR. et al.) New York: McGraw-Hill
Suzuki Y et al. (1997) D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency: a newly identified peroxisomal disorder. Am J Hum Genet 61: 1153–1162
Watkins PA et al. (1989) Peroxisomal bifunctional enzyme deficiency. J Clin Invest 83: 771–777
Ferdinandusse S et al. (2006) Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 59: 92–104
Suzuki Y et al. (1994) Novel subtype of peroxisomal acyl-CoA oxidase deficiency and bifunctional enzyme deficiency with detectable enzyme protein: identification by means of complementation analysis. Am J Hum Genet 54: 36–43
Johnson MR et al. (1991) Purification and characterization of bile acid-CoA: amino acid N-acyltransferase from human liver. J Biol Chem 266: 10227–10233
Wheeler JB et al. (1997) Purification and characterization of a rat liver bile acid coenzyme A ligase from rat liver microsomes. Arch Biochem Biophys 348: 15–24
Carlton VE et al. (2003) Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Gen 34: 91–96
Falany CN et al. (1994) Glycine and taurine conjugation of bile acids by a single enzyme: molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem 269: 19375–19379
Falany CN et al. (2002) Molecular cloning and expression of rat liver bile acid CoA ligase. J Lipid Res 43: 2062–2071
Ueki I et al. (2008) Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7α-hydroxylase gene. J Pediatr Gastroenterol Nutr 46: 465–469
Acknowledgements
RJS and SSS are supported by NIH grants U54DK078377, UO1DK062453 and RR00069.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sundaram, S., Bove, K., Lovell, M. et al. Mechanisms of Disease: inborn errors of bile acid synthesis. Nat Rev Gastroenterol Hepatol 5, 456–468 (2008). https://doi.org/10.1038/ncpgasthep1179
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1179
This article is cited by
-
Neonatale Cholestase
Monatsschrift Kinderheilkunde (2021)
-
Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics
Nature Reviews Gastroenterology & Hepatology (2019)
-
Farnesoid X receptor and bile acids regulate vitamin A storage
Scientific Reports (2019)
-
Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities
Stem Cell Research & Therapy (2015)
-
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator
Molecular Neurodegeneration (2015)